#Dana-Farber Cancer Institute

Nearly 50 existing non-cancer drugs were found to kill some cancer cell lines in the lab.

Discussing details about symptoms can help come up with targeted suggestions.

A new study developed a model categorizing the disease, and a treatment’s likelihood of success, based on the tumor’s site of origin.

New insights may help scientists develop better drugs to intervene in cancers, such as melanoma and thyroid cancer

“Experimental evolution” analyses can determine the interactions that proteins use to fold into functional three-dimensional shapes.

Predicting who is likely or unlikely to respond to checkpoint inhibitors remains a focus for researchers.

Researchers are working to understand why tumors may be resistant to T-cell immunotherapy, and to identify novel targets for immunotherapy.

The difference in oxygen levels between cancer cells and normal cells continues to inspire research.

Study focused on people who have exhausted available therapies but want to continue with treatment.

Foods can be ‘healthy,’ but are they healthy for somebody right now who is undergoing treatment?

The bottom line is that people risk not having their genetic alterations identified if they do not have genetic consultations.

Chances are, whether you are a patient or caregiver, you have been stronger in the past year than you thought you were capable of.

In a recent study, Dana-Farber scientists and others uncovered a key part of why some patients eventually become resistant to Venclexta.

The disparity is likely due in part to a low representation of minority physicians in cancer subspecialties.

A study shows how “epigenetic” changes can lead to the development of certain cancers, and how to short-circuit the cancer-causing machine...

“To understand cancer better, we need the combination of chemistry, biology, chemical biology, computational biology and bioinformatics.”